Aisaka K, Kaneda S, Tsuzuki H, Toriya Y, Kokuho K, Tamechika S, Saitoh H, Yoshida K, Mori H
Department of Obstetrics & Gynecology, San-ikukai Hospital, Tokyo, Japan.
Nihon Naibunpi Gakkai Zasshi. 1993 Oct 20;69(9):1017-27. doi: 10.1507/endocrine1927.69.9_1017.
It is well known that the transient excessive increase of serum prolactin level is harmful for the mechanism of ovulation or the steroidogenesis of the ovaries. The pathogenesis of latent or occult hyperprolactinemia (OHP) has been investigated recently. The present study was conducted to determine the diagnostic standard of OHP, and to elucidate the efficacy of bromocriptine administration for the treatment of OHP and other ovulatory disturbances. 110 cases of hypothalamic anovulations were selected from 385 cases of infertile patients by the LH-RH and TRH loading tests. Bromocriptine (5mg/day) was administered to all of the subjects for more than three months, and the efficacy of the bromocriptine administration was investigated. Follicular development was observed by transvaginal ultrasonography (mature follicular diameters > or = 20mm), and also luteal function was estimated by the duration of the luteal phase in the BBT charts (high phase > or = 12 days), the mid-luteal serum estradiol (> or = 200pg/ml) and progesterone (> or = 10ng/ml) levels. The subjects were divided into two groups: group A, bromocriptine effective patients (63 cases) and group B, bromocriptine non effective patients (47 cases). The results of the LH-RH and TRH loading tests were compared between these two groups. Serum prolactin levels at 30 min. after TRH loading (PRL30) in group B (61.5 +/- 28.3 vs. 38.0 +/- 19.3ng/ml, p < 0.01). At the cut-off points of 50, 60 and 70ng/ml over in the values of the PRL, the efficacies of the bromocriptine administration were 77.4, 78.9 and 88.5%, respectively. From these facts, it was thought suitable that the diagnostic standard of OHP was PRL30 > or = 70ng/ml, and values of PRL30 from 50 to 70ng/ml were borderline cases of OHP. The efficacy of the bromocriptine administration in the cases without OHP (n = 57) was also investigated. Serum LH levels at 30 min. after LH-RH loading (LH30) were compared between the cases of the bromocriptine effective (n = 22) and non effective (n = 35). As a result, the LH30 of the former was significantly higher than that of the latter (96.5 +/- 64.2 vs. 45.1 +/- 31.5mIU/ml, p < 0.005). In conclusion, the diagnostic standard of OHP was determined as PRL30 > or = 70ng/ml (borderline: 50 > 70ng/ml), and bromocriptine administration was effective not only in cases of OHP, but also in cases of hyperreactivities of LH (so-called endocrinological PCOD).
众所周知,血清催乳素水平的短暂过度升高对排卵机制或卵巢类固醇生成有害。近年来对隐匿性高催乳素血症(OHP)的发病机制进行了研究。本研究旨在确定OHP的诊断标准,并阐明溴隐亭治疗OHP及其他排卵障碍的疗效。通过LH-RH和TRH激发试验,从385例不孕患者中选取110例下丘脑性无排卵患者。所有受试者均服用溴隐亭(5mg/天)超过三个月,并研究溴隐亭的治疗效果。通过经阴道超声检查观察卵泡发育(成熟卵泡直径≥20mm),并通过基础体温图中的黄体期持续时间(高温相≥12天)、黄体中期血清雌二醇(≥200pg/ml)和孕酮(≥10ng/ml)水平评估黄体功能。受试者分为两组:A组,溴隐亭有效患者(63例)和B组,溴隐亭无效患者(47例)。比较两组LH-RH和TRH激发试验的结果。B组TRH激发后30分钟血清催乳素水平(PRL30)(61.5±28.3 vs. 38.0±19.3ng/ml,p<0.01)。在PRL值超过50、60和70ng/ml的截断点时,溴隐亭治疗的有效率分别为77.4%、78.9%和88.5%。基于这些事实,认为OHP的诊断标准为PRL30≥70ng/ml,PRL30在50至70ng/ml之间的值为OHP的临界病例。还研究了溴隐亭在无OHP患者(n = 57)中的疗效。比较溴隐亭有效(n = 22)和无效(n = 35)患者LH-RH激发后30分钟的血清LH水平(LH30)。结果,前者的LH30显著高于后者(96.5±64.2 vs. 45.1±31.5mIU/ml,p<0.005)。总之,OHP的诊断标准确定为PRL30≥70ng/ml(临界值:50>70ng/ml),溴隐亭不仅对OHP有效,而且对LH高反应性病例(所谓的内分泌性多囊卵巢综合征)也有效。